Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS

被引:102
作者
Villar, LM
Masjuan, J
González-Porqué, P
Plaza, J
Sádaba, MC
Roldán, E
Bootello, A
Alvarez-Cermeño, JC
机构
[1] Hosp Ramon & Cajal, Serv Immunol, Dept Immunol, Madrid 28034, Spain
[2] Hosp Ramon & Cajal, Dept Neurol, Madrid 28034, Spain
[3] Univ Alcala de Henares, Dept Med, Alcala De Henares, Spain
关键词
D O I
10.1212/WNL.59.4.555
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The authors have recently described that intrathecal IgM synthesis (ITMS) correlates with a higher disability in patients with clinically definite MS (CDMS). Objective: To follow-up a group of patients with MS in the initial stages of the disease to evaluate if the presence of ITMS correlates with a worse evolution. Methods: Oligoclonal IgM bands were performed in 22 patients with MS with a mean of 1.14 months of evolution. Patients were followed for a period ranging from 6 to 36 months (mean, 21.4 months). During follow-up, time to conversion to CDMS, number of relapses, and changes in Expanded Disability Status Scale (EDSS) score were evaluated. Results: Patients were divided into two groups according to the presence (Group 1, 10 patients) or absence (Group 2, 12 patients) of ITMS. No clinical differences were observed between the groups at inclusion in the study. During the follow-up, the probability of conversion to CDMS was greater in Group 1 (90% of the patients had converted to CDMS after 8 months of follow-up) than in Group 2 (51% of patients had converted to CDMS after 36 months of follow-up) (p = 0.0001). Patients from Group 1 had more relapses (mean, 2.0) than those from Group 2 (mean, 0.58) (p = 0.02). At the end of the study, patients from Group 1 had higher EDSS scores (mean, 1.70) than those from Group 2 (mean, 0.79) (p = 0.02). Conclusion: The presence of oligoclonal IgM bands in CSF can be a prognostic marker in the early phases of MS.
引用
收藏
页码:555 / 559
页数:5
相关论文
共 26 条
[11]  
Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO
[12]  
2-Q
[13]   14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis [J].
Martínez-Yélamos, A ;
Saiz, A ;
Sanchez-Valle, R ;
Casado, V ;
Ramón, JM ;
Graus, F ;
Arbizu, T .
NEUROLOGY, 2001, 57 (04) :722-724
[14]   Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GDIa [J].
Matà, S ;
Lolli, F ;
Söderström, M ;
Pinto, F ;
Link, H .
MULTIPLE SCLEROSIS, 1999, 5 (06) :379-388
[15]   NEW DIAGNOSTIC-CRITERIA FOR MULTIPLE-SCLEROSIS - GUIDELINES FOR RESEARCH PROTOCOLS [J].
POSER, CM ;
PATY, DW ;
SCHEINBERG, L ;
MCDONALD, WI ;
DAVIS, FA ;
EBERS, GC ;
JOHNSON, KP ;
SIBLEY, WA ;
SILBERBERG, DH ;
TOURTELLOTTE, WW .
ANNALS OF NEUROLOGY, 1983, 13 (03) :227-231
[16]   Immunopathology of secondary-progressive multiple sclerosis [J].
Prineas, JW ;
Kwon, EE ;
Cho, ES ;
Sharer, LR ;
Barnett, MH ;
Oleszak, EL ;
Hoffman, B ;
Morgan, BP .
ANNALS OF NEUROLOGY, 2001, 50 (05) :646-657
[17]   Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis [J].
Sadatipour, BT ;
Greer, JM ;
Pender, MP .
ANNALS OF NEUROLOGY, 1998, 44 (06) :980-983
[18]  
Sellebjerg F, 1998, MULT SCLER, V4, P127, DOI 10.1177/135245859800400307
[19]   THE PREDICTIVE VALUE OF INTRATHECAL IMMUNOGLOBULIN-SYNTHESIS AND MAGNETIC-RESONANCE-IMAGING IN ACUTE ISOLATED SYNDROMES FOR SUBSEQUENT DEVELOPMENT OF MULTIPLE-SCLEROSIS [J].
SHARIEF, MK ;
THOMPSON, EJ .
ANNALS OF NEUROLOGY, 1991, 29 (02) :147-151
[20]  
SHARIEF MK, 1991, BRAIN, V114, P181